182 related articles for article (PubMed ID: 24396969)
1. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
3. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
4. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
5. Incretin therapy and its effect on body weight in patients with diabetes.
Lind M
Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
Unger J
J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
Pratley RE
J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
[No Abstract] [Full Text] [Related]
8. Incretin-based therapies: where will we be 50 years from now?
Meier JJ; Nauck MA
Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in incretin-based therapies.
Russell-Jones D; Gough S
Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
[TBL] [Abstract][Full Text] [Related]
10. Incretins: the novel therapy of type 2 diabetes.
Thongtang N; Sriwijitkamol A
J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
[TBL] [Abstract][Full Text] [Related]
11. [Incretin and incretin-based therapies].
Harada N; Inagaki N
Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
[TBL] [Abstract][Full Text] [Related]
12. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
13. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
Grunberger G
J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
[TBL] [Abstract][Full Text] [Related]
14. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.
Vora J; Bain SC; Damci T; Dzida G; Hollander P; Meneghini LF; Ross SA
Diabetes Metab; 2013 Feb; 39(1):6-15. PubMed ID: 23022130
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing among incretin-based therapies. Introduction.
Campbell RK; Cobble ME; Reid TS; Shomali ME
J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
[TBL] [Abstract][Full Text] [Related]
17. Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.
Urquhart BS
Adv NPs PAs; 2010 Oct; 1(2):38-44. PubMed ID: 21299149
[No Abstract] [Full Text] [Related]
18. Increased priority for regimens involving incretin-based and insulin therapy.
Rodbard HW
J Fam Pract; 2013 Dec; 62(12 Suppl CME):S5-11. PubMed ID: 24340348
[TBL] [Abstract][Full Text] [Related]
19. Choosing among the incretin agents and why it matters.
Unger J
J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
[No Abstract] [Full Text] [Related]
20. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
Drab SR
Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
